Georgetown University
georgetown.eduTotal trials
284
Active
53
Phase 3
18
Total enrollment
71,459
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 40 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bevacizumab | — | — | — | — | 4 | ||
| Atezolizumab | — | — | — | — | 2 | ||
| Nivolumab | — | — | — | — | — | 5 | |
| Proglumide | — | — | — | 4 | |||
| Pembrolizumab | — | — | — | — | — | 4 | |
| Durvalumab | — | — | — | — | — | 3 | |
| Gemcitabine | — | — | — | — | 3 | ||
| Venetoclax | — | — | — | — | — | 2 | |
| Ipilimumab | — | — | — | — | — | 2 | |
| Tremelimumab | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | — | 2 | |
| Nab paclitaxel | — | — | — | — | 2 | ||
| Cemiplimab-Rwlc | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| TTP488 | — | — | — | — | — | 1 | |
| ddAC/ddT | — | — | — | — | — | 1 | |
| TC | — | — | — | — | — | 1 | |
| TCHP | — | — | — | — | — | 1 | |
| Chemotherapy regimen that includes ddAC | — | — | — | — | — | 1 | |
| Trans-Resveratrol | — | — | — | — | — | 1 | |
| Rituximab/Hyaluronidase Human | — | — | — | — | — | 1 | |
| CPX-351 | — | — | — | — | — | 1 | |
| BXCL701 | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| KRAS vaccine | — | — | — | — | — | 1 | |
| Sacituzumab govitecan-hziy | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Nanoliposomal Irinotecan | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| 192 mg powder of K0706 | — | — | — | — | — | 1 | |
| 384 mg powder of K0706 | — | — | — | — | — | 1 | |
| Talazoparib | — | — | — | — | — | 1 | |
| Avelumab | — | — | — | — | — | 1 | |
| MGC018 | — | — | — | — | — | 1 | |
| NY-ESO-1 Peptide vaccine | — | — | — | — | — | 1 | |
| Toripalimab-tpzi | — | — | — | — | — | 1 | |
| Tiragolumab | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | 2 | ||
| NEROFE | — | — | — | — | — | 1 |
Next readouts
- 2023-06
- 2023-08-08
- 2025-03-28
- 2025-09-03
- 2025-12-31
- 2026-04
- 2026-06-30
- 2026-07
- 2026-07
- 2026-12
Top conditions
- Breast Cancer28
- Prostate Cancer8
- Colorectal Cancer7
- Stroke7
- Lung Cancer6
- Chronic Lymphocytic Leukemia5
- Pancreatic Cancer5
- Metastatic Pancreatic Cancer5
Frequently asked questions about Georgetown University
- How many clinical trials does Georgetown University have on ClinicalTrials.gov?
- Georgetown University is listed as the lead sponsor on 284 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Georgetown University's trials are in Phase 3?
- 18 of Georgetown University's trials are in Phase 3, spread across 40 active drug programs.
- What therapeutic areas does Georgetown University focus on?
- Georgetown University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Prostate Cancer, Colorectal Cancer, Stroke, Lung Cancer.
- When are Georgetown University's next clinical trial readouts?
- Georgetown University has 10 upcoming primary-completion readouts tracked here; the soonest is “K0706 for Patients Diagnosed With Dementia With Lewy Bodies”, expected around 2023-06.